HC Wainwright Lowers XOMA (NASDAQ:XOMA) Price Target to $104.00

XOMA (NASDAQ:XOMAFree Report) had its price objective reduced by HC Wainwright from $123.00 to $104.00 in a research report released on Monday,Benzinga reports. HC Wainwright currently has a buy rating on the biotechnology company’s stock.

Separately, StockNews.com raised XOMA from a “sell” rating to a “hold” rating in a research report on Thursday, January 16th.

View Our Latest Research Report on XOMA

XOMA Trading Up 2.4 %

XOMA opened at $26.34 on Monday. The firm’s fifty day moving average is $27.42 and its two-hundred day moving average is $28.04. The firm has a market cap of $310.36 million, a PE ratio of -7.57 and a beta of 0.90. XOMA has a twelve month low of $19.50 and a twelve month high of $35.00. The company has a debt-to-equity ratio of 1.28, a quick ratio of 7.52 and a current ratio of 7.52.

XOMA (NASDAQ:XOMAGet Free Report) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.05. XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%. The business had revenue of $7.20 million for the quarter, compared to the consensus estimate of $6.66 million. Equities research analysts anticipate that XOMA will post -1.41 EPS for the current year.

Insider Activity at XOMA

In other XOMA news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of XOMA stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $26.10, for a total value of $13,069,366.20. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Owen Hughes sold 21,881 shares of the business’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $29.95, for a total value of $655,335.95. Following the completion of the sale, the chief executive officer now owns 34,979 shares in the company, valued at approximately $1,047,621.05. This trade represents a 38.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On XOMA

Several hedge funds have recently made changes to their positions in XOMA. Ellsworth Advisors LLC bought a new stake in shares of XOMA in the third quarter worth $516,000. BNP Paribas Financial Markets increased its stake in XOMA by 95.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 795 shares during the last quarter. State Street Corp lifted its position in XOMA by 1.2% during the 3rd quarter. State Street Corp now owns 142,857 shares of the biotechnology company’s stock worth $3,783,000 after buying an additional 1,754 shares in the last quarter. Barclays PLC boosted its stake in shares of XOMA by 300.7% during the 3rd quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock worth $298,000 after buying an additional 8,447 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of XOMA by 0.6% in the 3rd quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company’s stock valued at $4,840,000 after acquiring an additional 1,138 shares in the last quarter. 95.92% of the stock is owned by institutional investors.

XOMA Company Profile

(Get Free Report)

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.

See Also

Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.